Praxis Precision Medicines, Inc. (PRAX)
NASDAQ:PRAX
Want to see PRAX full AI Analyst Report?
PRAX Stock Chart & Stats
$342.50
-$2.82(-3.64%)
At close: 4:00 PM EST
$342.50
-$2.82(-3.64%)
Day’s Range― - ―
52-Week Range$37.19 - $366.52
Previous CloseN/A
Volume51.58K
Average Volume (3M)367.45K
Market Cap
$9.34B
Enterprise Value$6.86B
Total Cash (Recent Filing)$786.87M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Aug 10, 2026EPS Estimate
-3.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.39
Shares Outstanding27,878,775
10 Day Avg. Volume301,128
30 Day Avg. Volume367,450
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)7.55
Price to Sales (P/S)0.00
P/FCF Ratio-26.63
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-53.27
Enterprise Value/Ebitda-19.46
Forecast
1Y Price Target
$623.24Price Target Upside81.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-15.1
Revenue Forecast (FY)$4.21M
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength And RunwayA large cash position (~$1.4B) and extremely low debt give Praxis durable financial flexibility to fund late‑stage trials, regulatory work and initial commercial build through 2028. This reduces immediate refinancing risk and supports multi‑year program execution even if timelines slip.
Regulatory Progress With Set PDUFA DatesFormal NDA acceptance and calendarized PDUFA dates materially de‑risks development timing versus pre‑submission status. Having two reviewable assets creates clearer paths to potential approvals and allows the company to prioritize commercial investments and manufacturing scale across defined regulatory milestones.
Compelling Clinical Signals And Deep PipelineRobust efficacy in a randomized pediatric cohort and multiple late‑stage programs provide structural upside: strong signals improve probability of regulatory success and payer engagement, while a diversified neurology portfolio spreads binary program risk across assets and indications over the next 2–4 years.
Bears Say
High And Variable Cash BurnSustained negative operating and free cash flow at scale raises dilution and execution risk if regulatory or launch timelines extend. While cash on hand is strong today, elevated and growing burn tied to simultaneous late‑stage programs and commercialization could force financing or spending cuts if approvals are delayed.
No Meaningful Revenue; Structurally UnprofitableAs a clinical‑stage biotech Praxis lacks commercial revenue, so long‑term sustainability depends on trial outcomes, approvals and capital markets. Persistent large net losses mean shareholder returns hinge on successful launches and reimbursement, leaving high execution and funding dependency risk over the coming months and years.
Program Re‑evaluation After POWER1 MissA failed primary endpoint and an enrollment pause signal material development uncertainty for the vormatrigine program, implying potential timeline slips, added costs for redesign or additional studies, and weaker franchise optionality in focal epilepsy — increasing program failure and competitive risk.
Praxis Precision Medicines News
PRAX FAQ
What was Praxis Precision Medicines, Inc.’s price range in the past 12 months?
Praxis Precision Medicines, Inc. lowest stock price was $37.19 and its highest was $366.52 in the past 12 months.
What is Praxis Precision Medicines, Inc.’s market cap?
Praxis Precision Medicines, Inc.’s market cap is $9.34B.
When is Praxis Precision Medicines, Inc.’s upcoming earnings report date?
Praxis Precision Medicines, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 68 days.
How were Praxis Precision Medicines, Inc.’s earnings last quarter?
Praxis Precision Medicines, Inc. released its earnings results on May 07, 2026. The company reported -$3.2 earnings per share for the quarter, beating the consensus estimate of -$3.589 by $0.389.
Is Praxis Precision Medicines, Inc. overvalued?
According to Wall Street analysts Praxis Precision Medicines, Inc.’s price is currently Undervalued.
Does Praxis Precision Medicines, Inc. pay dividends?
Praxis Precision Medicines, Inc. does not currently pay dividends.
What is Praxis Precision Medicines, Inc.’s EPS estimate?
Praxis Precision Medicines, Inc.’s EPS estimate is -3.68.
How many shares outstanding does Praxis Precision Medicines, Inc. have?
Praxis Precision Medicines, Inc. has 27,878,775 shares outstanding.
What happened to Praxis Precision Medicines, Inc.’s price movement after its last earnings report?
Praxis Precision Medicines, Inc. reported an EPS of -$3.2 in its last earnings report, beating expectations of -$3.589. Following the earnings report the stock price went down -1.417%.
Which hedge fund is a major shareholder of Praxis Precision Medicines, Inc.?
Currently, no hedge funds are holding shares in PRAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Praxis Precision Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$623.24 (81.97% Upside)
$623.24 (81.97% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 832.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 44%
Bearish news 44%
Technicals
SMA
Positive
20 days / 200 days
Momentum
548.11%
12-Months-Change
Fundamentals
Return on Equity
-43.02%
Trailing 12-Months
Asset Growth
205.01%
Trailing 12-Months
Company Description
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
PRAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and clinical momentum: two NDAs accepted with PDUFA dates, rapid completion of a key EMBOLD study, an impressive 77% placebo‑adjusted seizure reduction in EMBRAVE Part A, multiple upcoming pivotal readouts, and a strengthened balance sheet ($1.4B, +51% vs. year‑end). Management is heavily investing in commercialization and late‑stage development (Q1 operating cash use +62% YoY), which raises short‑term cash burn and execution risk. Regulatory timing, heterogeneous populations in broad DEE, and U.S. pricing dynamics are notable uncertainties but are framed as manageable. On balance, the positive clinical data, regulatory progress, and substantial cash runway outweigh the cost and execution risks.View all PRAX earnings summariesPRAX Stock 12 Month Forecast
Average Price Target
$623.24
▲(81.97% Upside)
Technical Analysis
ARS Pharmaceuticals
―
AbCellera Biologics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
8.27% Insiders
25.37% Mutual Funds
51.61% Other Institutional Investors
0.17% Public Companies and Individual Investors